Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal tract. They are potentially malignant, and have an unpredictable evolution. The origin of these tumors is in the interstitial cells of Cajal, which are cells that are interposed between the intramural neurons and the smooth muscle cells of the digestive tract. GISTs are characterized by mutations in the gene c-Kit, but also other mutations, such as those of the platelet-derived growth factor receptor alpha. The most common locations of these tumors are the stomach and small intestine, although they can occur at any level of the digestive tract and occasionally in the omentum, mesentery and peritoneum. Most cases of GISTs are sporadic, and about 5% of cases are part of family genetic syndromes. The correct diagnosis of GIST is determined by histopathological examination and immunohistochemistry. According to histopathology, there are three main types of GISTs: spindle cell type, epithelioid type and mixed type. The therapeutic management of GIST includes surgery, endoscopic treatment and chemotherapy. The prognosis of patients with GIST varies depending on a number of factors, such as risk category, GIST stage, treatment applied and recurrence after treatment.

Background/Objectives: Inflammatory bowel diseases (IBDs) are chronic intestinal disorders with an unpredictable course. In parallel with the advent of new biologic therapies targeting specific interleukin pathways, end-point targets have become more stringent, aiming for mucosal and even histologic healing. Methods: We conducted a prospective study assessing immunohistochemical (IHC) parameters in 46 IBD patients treated with biologic therapy. A similar IHC analysis was performed for comparison with a cohort of 10 “non-IBD” patients. Results: The highest integrated optical density (IOD) of TNF-α was observed in patients with dysplasia, abscesses, mucin depletion and basal plasmacytosis. Non-responders had higher pre- and post-treatment TNF-α expression in both UC and CD compared to responders. On the contrary, the same analysis conducted in the subpopulation treated with anti-TNF-α therapy (Infliximab and Adalimumab) did not reveal a substantial difference in TNF-α expression between responders and non-responders. High pre-treatment interleukin-10 expression was associated with biologic therapy failure, histological inflammatory activity and longer disease duration. Conclusions: Pre-treatment assessment of IL-10 might be a useful tool for identifying a high-risk subset of IBD patients and determining a more aggressive therapy and intensive monitoring strategy.

Background/Objectives: Pancreatic metastases are uncommon and may resemble primary pancreatic neoplasms on imaging, making tissue confirmation essential. This study aimed to characterize pancreatic metastases diagnosed by endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) and to describe tissue adequacy within the confirmed cohort and procedure-related adverse events. Methods: This retrospective, single-center study included 21 patients with histologically confirmed pancreatic metastases diagnosed by EUS-FNB between January 2021 and November 2025. Clinical data, EUS features, procedural parameters, histopathological findings, management, and outcomes were reviewed. Results: The mean age was 60.9 ± 12.9 years, and 57.1% of patients were male. Lung carcinoma was the most frequent primary tumor (33.3%), followed by renal cell carcinoma (19.0%). Most lesions were solitary (66.7%) and hypoechoic (85.7%). All 21 patients included in the final cohort had histologically adequate EUS-FNB specimens; this finding reflects the selected cohort of confirmed metastatic cases and should not be interpreted as an overall adequacy rate or measure of diagnostic performance. The mean number of needle passes was 1.14 ± 0.36. One small, asymptomatic intrapancreatic hematoma occurred and resolved conservatively. Three selected patients underwent surgical resection and were alive without evidence of disease at last follow-up; however, no inference regarding a survival benefit from surgery can be made from this small, selected subgroup. Conclusions: In this cohort of histologically confirmed pancreatic metastases, EUS-FNB provided tissue suitable for pathological characterization, with immunohistochemical analysis performed when required to determine tumor origin. The present study was not designed to estimate overall diagnostic accuracy or adequacy. Surgical resection may be considered in carefully selected patients with isolated disease, as supported by the published literature; however, the present cohort does not permit assessment of a survival benefit associated with surgery.